A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs
Huoying Huang, Yuxin Zhou, Chengzhang Shang, Yifu Zhang, Yuelei Shen
Topics & Concepts
ConjugateAntibody-drug conjugateDrugMedicineBispecific antibodyDrug resistancePharmacologyCancer researchTrastuzumabAntibodyMonoclonal antibodyImmunologyCancerBiologyInternal medicineMicrobiologyMathematical analysisBreast cancerMathematicsHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchRadiopharmaceutical Chemistry and Applications